Skip to Content

4 Results Found

  • Article
  • Open Access
4 Citations
3,187 Views
8 Pages

Quantification of Canine Apocrine Gland Anal Sac Adenocarcinoma (AGASACA) Tumor Specimen Shrinkage after Formalin Fixation

  • Brandan G. Wustefeld-Janssens,
  • Arathi Vinayak,
  • Lindsay A. Parker and
  • Danielle L. Hollenbeck

22 July 2022

The aim was to prospectively measure the shrinkage of primary apocrine gland anal sac adenocarcinoma (AGASACA) tumors after 24 and 48 h of formalin fixation. Dogs that were diagnosed with AGASACA pre-operatively by aspiration cytology were prospectiv...

(This article belongs to the Special Issue Advances in Veterinary Oncology)
  • Article
  • Open Access
20 Citations
7,259 Views
17 Pages

Prognostic Value of Ki67 and Other Clinical and Histopathological Factors in Canine Apocrine Gland Anal Sac Adenocarcinoma

  • Emanuela Maria Morello,
  • Marzia Cino,
  • Davide Giacobino,
  • Arturo Nicoletti and ,
  • Selina Iussich,
  • Paolo Buracco and
  • Marina Martano
  • + 2 authors+ 0 author

2 June 2021

Apocrine gland anal sac adenocarcinoma (AGASACA) is locally aggressive and highly metastatic to regional lymph nodes. The aim of this study was to evaluate the prognostic significance of Ki67 in surgically excised AGASACA. Prognostic impact of size,...

(This article belongs to the Special Issue Oncology in Veterinary Medicine)
  • Article
  • Open Access
20 Citations
5,146 Views
12 Pages

Development of Monoclonal Antibodies Targeting Canine PD-L1 and PD-1 and Their Clinical Relevance in Canine Apocrine Gland Anal Sac Adenocarcinoma

  • Lucia Minoli,
  • Luca Licenziato,
  • Mikolaj Kocikowski,
  • Marzia Cino and ,
  • Katarzyna Dziubek,
  • Selina Iussich,
  • Antonella Fanelli,
  • Emanuela Morello,
  • Marina Martano and
  • Luca Aresu
  • + 8 authors+ 3 authors

14 December 2022

Canine apocrine gland anal sac adenocarcinoma (AGASACA) is an aggressive canine tumor originating from the anal sac glands. Surgical resection, with or without adjuvant chemotherapy, represents the standard of care for this tumor, but the outcome is...

(This article belongs to the Special Issue Checkpoint Markers and Cancer Microenvironment: What Do We Know?)